Oncocyte Corporation: Study Results Published in Clinical Cancer Research Journal
Precision diagnostic company, Oncocyte Corporation (Nasdaq: OCX) has announced the peer-reviewed publication of the results of a study applying its DetermaIO™ diagnostic to samples collected from a randomized Phase II clinical trial in metastatic colorectal cancer.
The study’s results showed the utility of DetermaIO in potentially identifying more responders to immune checkpoint inhibitor (ICI) therapy than current standard of care biomarkers.
DetermaIO is a proprietary gene expression test that assesses the entire Tumor Immune Microenvironment (TIME) to identify the patients most likely to benefit from immunotherapy.
In a population of 122 patients, DetermaIO-positive patients achieved better outcomes in terms of progression-free survival than DetermaIO negative patients.
A similar trend was observed in a population of 110 proficient mismatch repair (pMMR) patients. pMMR patients do not currently qualify for ICI therapy in metastatic colorectal cancer.
The study’s authors concluded that DetermaIO provided the opportunity to identify an immune-enriched tumor microenvironment among pMMR tumors that do not currently qualify for ICI therapy.
Data showing strong associations between DetermaIO results and benefit from ICI therapy has been published and presented in multiple tumor types including advanced non-small cell lung cancer (NSCLC), triple negative breast cancer (TNBC), urothelial cancer, and colorectal cancer.
About Oncocyte Corporation
Oncocyte is a precision diagnostics company. The Company’s tests are designed to help provide clarity and confidence to physicians and their patients. DetermaIO™ is a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies. VitaGraft™ is a blood-based solid organ transplantation monitoring test, and pipeline test DetermaCNI™ is a blood-based monitoring tool for monitoring therapeutic efficacy. DetermaIO™, DetermaCNI™, and VitaGraft™ are trademarks of Oncocyte Corporation.